Jefferies Maintains a Buy on Enovis (ENOV), Sets a $60 PT
A patient recieving cold therapy treatment using the company's products.
Its net sales for the quarter grew 8% on a reported basis compared to the same quarter in 2024, while adjusted EBITDA reached $99 million, or 17.7% of sales. This translates to a 160 basis points growth compared to last year.
The analyst attributed the growth to the company's successful commercial execution and integration efforts, as well as additional potential from cross-selling opportunities and new product launches.
Enovis Corporation (NYSE:ENOV) is also increasing its free cash flow conversion and expanding margins, which positions it well for future profitability. The analyst further reasoned that the company has an attractive valuation and is trading below its peers, which points toward the potential for multiple expansions.
Enovis Corporation (NYSE:ENOV) is a medical technology growth company that develops clinically differentiated solutions to transform workflows and generate better patient outcomes. The company operates through the Prevention & Recovery and Reconstructive segments.
While we acknowledge the potential of ENOV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
Stifel Sees More Upside for Celestica (CLS) as AI Demand Accelerates
Celestica Inc. (NYSE:CLS) is one of the . On July 29, Stifel analyst Ruben Roy raised the price target on the stock to $230.00 (from $150.00) while maintaining a 'Buy' rating. The rating affirmation follows Celestica's better-than-expected F2Q25 results and raised guidance for FY26. The company continues to demonstrate robust execution on the back of AI-driven demand acceleration. 'CLS reported better-than-expected F2Q25 results, guided F3Q25 above consensus, and raised FY26 guidance. As such, we are raising our forward estimates, increasing our price target to $230, and reiterating our Buy rating as CLS continues to demonstrate strong execution amid AI-driven demand acceleration. F2Q25 sales of $2.89bn increased 9% sequentially and 21% y/y, with the CCS and ATS segments exhibiting 28% and 7% y/y growth, respectively (both exceeding management's prior expectations)." Celestica Inc., a provider of supply chain solutions, operates through two segments, Advanced Technology Solutions, and Connectivity and Cloud Solutions. While we acknowledge the potential of CLS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Must-Watch AI Stocks on Wall Street and Disclosure: None. Sign in to access your portfolio
Yahoo
33 minutes ago
- Yahoo
Vertiv's (VRT) Strong Q2 and AI Tailwinds Prompt Analyst Price Target Hike
Vertiv Holdings Co (NYSE:VRT) is one of the . On July 31, Oppenheimer analyst Noah Kaye raised the price target on the stock to $151.00 (from $140.00) while maintaining an Outperform rating. According to the analyst, Vertiv's record quarterly orders are an evidence to its market share gains. This ties with the company's efforts to help customers launch faster by expanding capacity, offering modular and prefab solutions, and aligning products with AI infrastructure needs. 'Shares were up Wednesday after VRT beat 2Q25 top-/bottom-line consensus and guided 2H above the Street while posting record quarterly orders. Results/outlook imply clear share gains in our view and connect to VRT's efforts to enable customer speed-to-market through capacity expansion, modular/prefab solutions, and portfolio alignment with AI infrastructure requirements." Vertiv Holdings Co (NYSE:VRT) is a global provider of digital infrastructure technology and services for data centers, communication networks, and commercial and industrial facilities. While we acknowledge the potential of VRT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Must-Watch AI Stocks on Wall Street and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
B&G Foods (BGS) Q2 Earnings: What To Expect
Packaged foods company B&G Foods (NYSE:BGS) will be reporting results this Monday afternoon. Here's what you need to know. B&G Foods missed analysts' revenue expectations by 6.8% last quarter, reporting revenues of $425.4 million, down 10.5% year on year. It was a disappointing quarter for the company, with a significant miss of analysts' adjusted operating income estimates and a significant miss of analysts' EBITDA estimates. Is B&G Foods a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting B&G Foods's revenue to decline 3.4% year on year to $429.6 million, improving from the 5.3% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.06 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. B&G Foods has missed Wall Street's revenue estimates four times over the last two years. Looking at B&G Foods's peers in the shelf-stable food segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Hershey delivered year-on-year revenue growth of 26%, beating analysts' expectations by 3.1%, and Lamb Weston reported revenues up 4%, topping estimates by 5.7%. Hershey's stock price was unchanged after the resultswhile Lamb Weston was up 19.3%. Read our full analysis of Hershey's results here and Lamb Weston's results here. The outlook for 2025 remains clouded by potential trade policy changes and corporate tax discussions, which could impact business confidence and growth. While some of the shelf-stable food stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 2.4% on average over the last month. B&G Foods's stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $5.42 (compared to the current share price of $4.19). When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we've found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
